Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating JUVÉDERM® VOLUMA® XC Injectable Gel for Correction of Temple Hollowing in Adult Participants ≥ 22 Years Old

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants in general good health~* Participants seeking improvement of temple hollowing~Exclusion Criteria:~* Temple hollowing due to trauma, congenital malformations, or lipodystrophy~* Temporomandibular joint dysfunction or any other jaw issues~* Recurrent temporal headaches such as temporal tendinitis migraine~* Active autoimmune disease~* History of anaphylaxis or allergy to lidocaine (or any amide-based anesthetics), HA products, or Streptococcal protein~* Prior facial reconstructive surgeries, facelift, or browlift as well as surgeries on the temple area (eg, biopsy)~* Fat injection or permanent facial implants anywhere in the face~* Semipermanent soft-tissue filler treatment in the temple or mid-face within 36 months before enrollment~* Temporary dermal filler injections above the subnasale within 24 months before enrollment~* Mesotherapy or cosmetic facial procedures above the subnasale within 6 months before enrollment~* Botulinum toxin treatment above the subnasale within 6 months before enrollment~* Females who are pregnant, nursing, or planning a pregnancy

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No Treatment then JUVÉDERM® VOLUMA® XC (Type: OTHER): Participants received no treatment for 3 months during the Control Period. They either exited the study at Month 3 or received an optional treatment with JUVÉDERM® VOLUMA® XC injectable gel treatment in both temples during the Post-Control Period and an optional touch-up treatment 30 days later. Participants did not receive any treatment during the Maintenance Treatment Period.
- JUVÉDERM® VOLUMA® XC (Type: EXPERIMENTAL): Participants received JUVÉDERM® VOLUMA® XC injectable gel treatment in both temples during the Control Period followed by an optional touch-up treatment 30 days later. Participants exited the study at Month 13 or received an optional maintenance treatment and were followed for 6 months during the Maintenance Treatment Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).